Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Down 5.2% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company known for its innovative treatments in various medical fields, including eye diseases.

Why is Regeneron Pharmaceuticals Inc. going down?

REGN stock is down 5.2% on Dec 19, 2024 14:45

• The bearish movement in REGN today could be attributed to Eylea HD showing non-inferiority to Eylea in a phase III study, raising concerns about potential competition within Regeneron's product line.
• The announcement of REGN's presentation at the J.P. Morgan Healthcare Conference might not have met market expectations for clear growth strategies or developments.
• The successful results of Eylea's higher dose formulation in treating another form of retinal disease might have been overshadowed by concerns about declining Eylea sales. This mixed performance of their lead drug could have influenced the bearish sentiment surrounding REGN.
• Overall, the market's reaction to recent events and REGN's performance this year, with a 15.5% decline, suggests investors are adopting a cautious approach, waiting for clearer signals of growth and stability before making significant moves in the stock.

REGN Price Chart

REGN Technical Analysis

REGN News

REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study

Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.

https://www.zacks.com/stock/news/2385344/regns-eylea-hd-shows-non-inferiority-to-eylea-in-eye-disease-study

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - Regeneron Pharmaceuticals ( NASDAQ:REGN )

TARRYTOWN, N.Y., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time ( 5:15 p.m.

https://www.benzinga.com/pressreleases/24/12/g42540015/regeneron-announces-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time ( 5:15 p.m.

https://www.globenewswire.com/news-release/2024/12/17/2998617/0/en/Regeneron-Announces-Presentation-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html

Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study - Regeneron Pharmaceuticals ( NASDAQ:REGN )

On Tuesday, Regeneron Pharmaceuticals, Inc. REGN announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD ( aflibercept ) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion ( RVO )

https://www.benzinga.com/24/12/42536756/regenerons-best-selling-eye-drug-eyleas-higher-dose-formulation-meets-primary-goal-in-another-form-of-retinal-dis

Regeneron Down 15.5% Year to Date: How to Play the Stock?

REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.

https://www.zacks.com/stock/news/2383265/regeneron-down-155-year-to-date-how-to-play-the-stock

Trending Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 5.2% Today

Horizen ($ZEN) Crypto Forecast: Up 7.6% Today

Algorand ($ALGO) Crypto Forecast: Up 10.7% Today

Aave ($AAVE) Crypto Forecast: Up 10.5% Today

Injective ($INJ) Crypto Forecast: Up 5.7% Today

Toncoin ($TON) Crypto Forecast: Up 5.4% Today

NEO ($NEO) Crypto Forecast: Up 5.1% Today

Floki ($FLOKI) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.3% Today

Litecoin ($LTC) Crypto Forecast: Up 5.0% Today

Regeneron Pharmaceuticals Inc. Price History

31.09.2024 - REGN Stock was down 9.7%

• Despite reporting better-than-expected third-quarter results with increased earnings and revenue, REGN experienced a bearish movement.
• The market may have reacted negatively due to investors possibly having higher expectations or concerns about future growth prospects.
• Even though the company's performance was strong, market sentiment and external factors could have influenced the stock's decline.
• It's essential for investors to consider both the company's financial results and market dynamics when analyzing stock movements.

31.09.2024 - REGN Stock was down 6.9%

• The recent bearish movement in REGN may be linked to investor caution preceding the third-quarter earnings. Concerns may arise regarding the performance of key products like Dupixent and the adoption of Eylea HD.
• While REGN has displayed long-term market outperformance, short-term fluctuations can be influenced by quarterly outcomes and investor sentiment.
• Amid uncertainties in the biotech sector and broader market conditions, investors could be reassessing their positions in REGN.

24.08.2024 - REGN Stock was down 8.1%

• Smart money has shown bearish behavior with REGN options, indicating a bearish sentiment among traders.
• This change in sentiment from financial giants may have contributed to REGN's bearish movement.
• Analyst downgrades for companies like Baidu Inc. (NYSE: BIDU) could impact overall market sentiment, indirectly influencing REGN's stock performance.
• The strong bearish movement in REGN today appears to be influenced by negative analyst outlook and bearish options activity.

24.08.2024 - REGN Stock was down 6.8%

• Chief District Judge Thomas Kleeh's rejection of Regeneron Pharmaceuticals' attempt to halt the sale of Amgen Inc's Eylea biosimilar likely influenced the bearish movement in REGN stock.
• The options market exhibited a notable bearish trend toward Regeneron Pharmaceuticals, indicating a considerable number of traders expressing bearish views.
• The prevailing negative market sentiment, portrayed by analyst downgrades affecting companies like BP and Baidu, potentially intensified the downward pressure on REGN stock.
• Investors are keeping a close watch on the legal proceedings and options market sentiment to assess the future direction of Regeneron Pharmaceuticals' stock.

15.10.2024 - REGN Stock was down 5.4%

• The FDA accepting the resubmission of the supplemental biologics license application for Regeneron's Dupixent indicates a potential positive development for the company.
• However, the market might have reacted bearishly due to uncertainty surrounding the outcome of the FDA review process.
• The investor conference presentations could have failed to provide significant new insights or positive catalysts, contributing to the bearish movement in the stock price.
• Investors might be cautious about the competitive landscape in the inflammatory skin disease market, leading to profit-taking and a downward trend in REGN's stock.

23.08.2024 - REGN Stock was down 5.1%

• Smart money is betting big on bearish options for REGN, with a notable increase in bearish trades.
• The high percentage of bearish traders indicates a prevailing sentiment of negativity towards REGN in the options market.
• This bearish movement could be attributed to concerns or uncertainties surrounding Regeneron Pharmaceuticals' future prospects or recent developments within the company.
• Investors might be reacting to specific news or events that have cast a shadow on REGN's short-term outlook, leading to the bearish market movement.

31.09.2024 - REGN Stock was down 10.8%

• REGN's Q3 earnings and revenues exceeded expectations, attributed to robust sales of Eylea HD and Dupixent.
• The market exhibited a bearish reaction post-results, possibly due to profit-taking following a period of solid performance.
• Concerns around REGN's growth sustainability and industry competition might have fueled investor caution, contributing to the bearish sentiment.
• Short-term dynamics appear to influence the market's sentiment towards REGN, possibly diminishing focus on the company's solid fundamentals and product range.

09.11.2024 - REGN Stock was up 2.9%

• Despite concerns about Navitas Semiconductor's financial performance, investors seem to be more focused on the positive outlook for LandBridge and Eli Lilly, which could be boosting overall market confidence.
• The bullish movement in REGN may also be attributed to positive developments in the biotechnology sector or specific company news that has driven investor optimism.
• An endorsement of LandBridge as a 'winner' could be influencing market sentiment positively, potentially spilling over to other related stocks like REGN.
• Overall, the bullish movement in REGN today could be a result of a combination of sector-specific tailwinds, positive company news, and investor sentiment influenced by comments from a market analyst.

19.11.2024 - REGN Stock was down 5.2%

• The bearish movement in REGN today could be attributed to Eylea HD showing non-inferiority to Eylea in a phase III study, raising concerns about potential competition within Regeneron's product line.
• The announcement of REGN's presentation at the J.P. Morgan Healthcare Conference might not have met market expectations for clear growth strategies or developments.
• The successful results of Eylea's higher dose formulation in treating another form of retinal disease might have been overshadowed by concerns about declining Eylea sales. This mixed performance of their lead drug could have influenced the bearish sentiment surrounding REGN.
• Overall, the market's reaction to recent events and REGN's performance this year, with a 15.5% decline, suggests investors are adopting a cautious approach, waiting for clearer signals of growth and stability before making significant moves in the stock.

03.05.2024 - REGN Stock was up 2.1%

• The bullish movement in REGN stock today can be attributed to the following factors:
• The FDA's decision to delay the verdict on Dupixent in COPD until September may have created anticipation and optimism among investors, as it indicates the regulatory body's thorough review and potential positive outcome.
• The recommendation for EU approval of Dupixent to treat COPD patients by CHMP could have boosted investor confidence in the drug's efficacy and market potential.
• The announcement of Neurocrine's CEO stepping down might have indirectly impacted REGN's stock positively, as it could signal upcoming strategic changes within the pharmaceutical industry that investors perceive as favorable.
• Overall, these developments surrounding Dupixent and regulatory approvals suggest a promising future for Regeneron Pharmaceuticals, driving the bullish market movement observed today.

01.07.2024 - REGN Stock was up 3.6%

• REGN stock showed significant upward momentum recently.
• This positive trend is due to Regeneron exceeding expectations in its latest financial results, fueled by strong demand for its eczema and eye treatments.
• The company posted impressive Q2 2024 financial and operational figures, including a notable rise in net income and revenue, alongside the approval of Dupixent for COPD in the EU.
• Investor confidence in REGN was further boosted by the substantial increase in EYLEA HD sales and the progress of over 35 candidates in the company's product pipeline.

02.07.2024 - REGN Stock was up 0.2%

• Regeneron Pharmaceuticals outperformed expectations in the second quarter, reporting earnings per share of $11.56, marking a 13% increase from the previous year, and total revenues of $3.54 billion, a 12% rise.
• The strong demand for eczema and eye treatments like Dupixent and Eylea HD significantly contributed to the company's impressive performance, driving a positive movement in its stock value.
• The company's ability to meet market demand for its innovative pharmaceutical products, resulting in better-than-anticipated results and revenue growth, has bolstered investor confidence and elevated its stock price.
• Regeneron's success in delivering popular treatments and surpassing earnings projections has pushed its stock on an upward trajectory, outperforming its industry counterparts and fostering a favorable market outlook.